111 Capital Iovance Biotherapeutics, Inc. Transaction History
111 Capital
- $582 Billion
- Q2 2025
A detailed history of 111 Capital transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, 111 Capital holds 11,809 shares of IOVA stock, worth $26,334. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,809Holding current value
$26,334% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IOVA
# of Institutions
316Shares Held
244MCall Options Held
1.39MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA25.1MShares$55.9 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$54.5 Million12.15% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$47.3 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY12.7MShares$28.3 Million1.77% of portfolio
-
State Street Corp Boston, MA9.89MShares$22.1 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $352M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...